Conducting a pivotal Phase 3 clinical trial (NCT06709014) evaluating buntanetap over 18 months in early Alzheimer's disease patients. The trial features a dual design: a 6-month symptomatic efficacy readout followed by an 18-month disease-modifying efficacy readout.

Expected impact: Provides the clinical data package required to support the company's first NDA submissions for buntanetap in Alzheimer's disease.

Executing a 36-month open-label extension study (ANVS-25002 / NCT07284784) to evaluate the long-term safety, tolerability, and efficacy of buntanetap in Parkinson's disease patients, including those from prior trials and patients undergoing deep brain stimulation.

Expected impact: Generates long-term safety and biomarker data to support the clinical profile and future regulatory filings for buntanetap in Parkinson's disease.

Executing strategic financial measures to secure the company's capital runway and restore compliance with NYSE listing standards. This included a $10 million public offering and a $1.5 million board investment in April 2026, alongside corrective actions to raise market capitalization and stockholders' equity.

Expected impact: Secures the company's listing on the NYSE and extends its cash runway through Q2 2027, fully funding operations through key clinical readouts.